On August 31, 2010, Salix Pharmaceuticals and its Dutch partner Norgine B.V. reached a settlement with New Jersey-based Novel Laboratories. This agreement allows Novel to distribute a generic version of the laxative medication MoviPrep®. Once approved by the U.S. District Court of New Jersey, Novel Laboratories will be able to sell a generic version of the drug and will act a as a domestic supply partner to Salix. This agreement would also void a pending lawsuit where Novel disputed the validity of Salix's pharmaceutical patent.
The court settlement includes a sub-license agreement that allows Novel to manufacture MoviPrep and to act as a domestic brand supplier for Salix and Norgine. The terms of the agreement permit Novel to license MoviPrep patents and to distribute generic versions of the medication no later than September 24, 2018, and as early as 2011. The acceptance of this consent judgment allows the court to dismiss all other pending complaints related to the medication.
North Carolina-based Salix Pharmaceuticals is a publicly traded pharmaceutical company that develops medications for gastrointestinal problems. The company licenses late-stage drugs and markets products through a team of gastroenterology sales specialists. Novel Laboratories is a comprehensive pharmaceutical company that develops, manufactures and distributes generic medications and niche medical products.
Keeping an eye on pharmaceutical companies
Dangerous drugs cause hundreds of deaths and thousands of serious complications each year. If you've been injured by a hazardous pharmaceutical medication or a dangerous medical device, contact the Savannah-based personal injury attorneys at Tate Law Group. The group's experienced attorneys represent patients who have been harmed by Zoloft®, Actos®, Pradaxa®, Fosamax® and DePuy joint implants. Our attorneys accept local lawsuits and multidistrict litigation cases. Call today to discuss your case with a compassionate personal injury attorney.